Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus

Objective: Plasmacytoid dendritic cells (pDCs) are a major source of Type-I Interferon (IFN-I), a key driver in cutaneous lupus erythematosus (CLE). Currently evaluated in Phase II clinical trial, 24F4A (BIIB059) is an antibody targeting BDCA2, an inhibitory receptor expressed on pDCs. Given that Hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardet, Agnes, Pellerin, Alex, McCarl, Christie-Ann, Diwanji, Rohan, Wang, Wenting, Donaldson, Douglas, Franchimont, Nathalie, Werth, Victoria P., Rabah, Dania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394354/
https://www.ncbi.nlm.nih.gov/pubmed/30846987
http://dx.doi.org/10.3389/fimmu.2019.00275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394354/
https://www.ncbi.nlm.nih.gov/pubmed/30846987
http://dx.doi.org/10.3389/fimmu.2019.00275

Ejemplares similares